BioPharm Brief: Dermatology, Neurology, and Oncology Updates

Welcome to the BioPharm Brief—your daily snapshot of the latest developments in the biopharmaceutical industry.

Three developments this week highlight both the opportunities and challenges facing biopharmaceutical development.

First, the FDA approved an update to the label for Lilly's Ebglyss (lebrikizumab), allowing eligible patients with moderate-to-severe atopic dermatitis to receive maintenance dosing once every eight weeks after achieving clinical response. The expanded dosing schedule is supported by long-term data demonstrating durable disease control while reducing treatment frequency, a change that could improve convenience for patients managing chronic inflammatory skin disease.

In neurology, Sanofi announced it is discontinuing the Phase 3 MOBILIZE trial of riliprubart in patients with treatment-refractory chronic inflammatory demyelinating polyneuropathy, or CIDP. An independent data monitoring committee determined the study was unlikely to demonstrate sufficient efficacy, although no new safety concerns were identified. Sanofi said it will further analyze the data and evaluate the future of other ongoing riliprubart studies, including the Phase 3 VITALIZE trial.

Finally, Kyowa Kirin will present new data on mogamulizumab at the World Congress of Cutaneous Lymphomas. The presentations include patient-reported outcomes, comparative-effectiveness analyses, biomarker research, and real-world evidence in relapsed or refractory mycosis fungoides and Sézary syndrome. The findings are intended to provide a broader understanding of the therapy's performance beyond the pivotal MAVORIC trial that supported its approval.

These developments reflect the diverse realities of drug development, from regulatory advances and label expansions to late-stage clinical setbacks and the growing importance of real-world evidence in understanding treatment outcomes.

That's all for today's BioPharm Brief. For further analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• Lebrikizumab gains a more convenient maintenance dosing schedule for patients with atopic dermatitis.
• Sanofi halts a Phase 3 CIDP trial after a futility analysis, despite no new safety concerns.
• Kyowa Kirin expands the evidence base for mogamulizumab with new clinical and real-world data in cutaneous T-cell lymphoma.